ICD-10-PCS › X New Technology › XW Anatomical Regions › XW0 New Technology, Anatomical... › XW04372

XW04372

Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

ValidICD-10-PCS procedure code.

Valid for claims with a date of service in the current code year.

Valid FY2017 onwards.

What has happened to this code

Every change the publisher made, from 2017 to now.

  1. FY2017 Added to the code set Introduction of Andexanet Alfa, Factor Xa Inhibitor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 2
  2. FY2020 Description revised Introduction of Andexanet Alfa, Factor Xa Inhibitor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 2 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

What this code says

Each character is read in its own position, so the same letter means different things in different places. Definitions are CMS's own.

3. Root operation Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

5. Approach Percutaneous

Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure

6. Device / Substance / Technology Coagulation Factor Xa, Inactivated

For example

  • Andexanet Alfa, Factor Xa Inhibitor Reversal Agent
  • Andexxa
  • Coagulation Factor Xa, (Recombinant) Inactivated
  • Factor Xa Inhibitor Reversal Agent, Andexanet Alfa

Codes in the same group

CodeDescriptionStatus
XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 Retired
XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Valid
XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Valid
XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 Valid
XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 Valid
XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 Valid
XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 Retired
XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 Valid
XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 Valid
XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 Valid